EHVA Halts Clinical Trial to Test a Candidate Therapeutic HIV Vaccine and Immunotherapy Drug

Back to the "News" list

Paris, 22 November, 2022 – The European HIV Vaccine Alliance (EHVA) announces that the EHVA T02 / ANRS VRI07 trial, a randomized, placebo-controlled Phase II trial evaluating an investigational therapeutic HIV vaccine and immunotherapy drug, vedolizumab, for people living with HIV has been halted. The trial was initially planned to take place in France, Germany, Switzerland and the United Kingdom.

Enrolment in the trial commenced in late June this year. However, it proved to be very challenging to recruit sufficient numbers of participants, which meant that the study most likely could not be completed as planned. This triggered a decision by the trial team and EHVA, in consultation with the trial authorities and representatives of the European AIDS Treatment Group, to stop enrolment in the trial in order to safeguard the interests of participants already included in the trial. A social science study conducted by INSERM on behalf of EHVA to assess motivations of people to participate in trials like EHVA T02 remains active to help inform future trials.

All members of EHVA would like to express their gratitude to those who participated in EHVA T02, the clinical research centres who helped prepare for the trial, members of the community of people living with HIV who helped inform the trial protocol, and everyone who expressed their support and interest in the trial. The development of therapeutic HIV vaccine strategies remains a priority for EHVA.

Source : EHVA

No posts found…

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?


Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.